46 results about "Cannabigerol" patented technology

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The utility model relates to industrial hemp extraction technical field, concretely relates to a hemp residue recovery and storage device based on industrial hemp extraction cannabigerol, including box, the inside assembly of box has the collecting device that carries out collection to impurity, the front of box is hinged with the box door, the collecting device includes roof, the roof fixed connection in the top of box, the fixed connection of electric telescopic link has in the roof inner wall bottom, the fixed connection of electric telescopic link output end bottom has the pressure plate, the fixed connection of box inner wall front has the supporting plate, the bottom of supporting plate inner wall is provided with the through -hole, the fixed connection of pressure plate top has the magnetism guide, the magnetism guide magnetic force is connected with permanent magnet. The utility model pressure plate presses down, magnetism guide and permanent magnet synchronous drop, rack drive first round tooth and second round tooth gear, first knock block and second knock block knock the sidewall of box and supporting plate bottom in proper order, through vibration stripping, solve the suspended and attached dust that traditional compression can not remove.

The invention provides a pharmaceutical formulation containing a particulate porous adsorbent selected from the group of aluminosilicates and their salts, with a neutral or basic pH and a particle size between 50 and 800 μm, onto which a mixture of polyoxyethylene sorbitan monooleate (polysorbate 80) is applied with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC, and D8-THC. This formulation improves the bioavailability and release profile of the cannabinoids.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

There is disclosed a composition comprising delta-9-tetrahydrocannabinol, cannabidiol, cannabigerol and a terpene component.

The invention discloses a method for rapidly detecting ten cannabinoids in industrial hemp fresh floral leaves based on an HPLC (High Performance Liquid Chromatography) method. The method comprises the following steps: S1, preparing a mixed standard solution; s2, pretreatment of a fresh industrial cannabis sativa floral leaf sample: liquid nitrogen grinding wall breaking, solvent ultrasonic extraction and low-temperature centrifugation are carried out, and a supernatant is taken for sample preparation; and S3, high performance liquid chromatography determination. The ten cannabinoids disclosed by the invention comprise cannabidiol (CBD), cannabidiol acid (CBDA), hypocannabidiol (CBDV), tetrahydrocannabinol acid (THCA), delta 9-tetrahydrocannabinol (delta 9-THC), delta 8-tetrahydrocannabinol (delta 8-THC), hypocannabinol (THCV), cannabinoid phenol (CBG), cannabinol (CBN) and cannabinocene (CBC). According to the method, the situation that carboxylic acid cannabinoid in fresh floral leaves is prone to decarboxylation conversion in the pretreatment process is fully considered, low-temperature extraction is conducted through liquid nitrogen grinding wall breaking, and it is ensured that carboxylic acid cannabinoid is stable. The detection method disclosed by the invention realizes high-throughput detection of 10 cannabinoids, can rapidly, objectively, accurately and synchronously detect various cannabinoids including carboxylic acid cannabinoids in fresh industrial hemp floral leaves, and has the advantages of short detection time (not exceeding 15 minutes), accurate quantification, reliable result, high efficiency and the like; and a reliable basis can be provided for industrial hemp characteristic variety breeding and scientific harvesting.

The invention discloses a cannabinoid phenol antibacterial peptide simulant with broad-spectrum antibacterial activity as well as a preparation method and application of the simulant. The simulant has a structure as shown in a formula (I): # imgabs0 # formula (I). The preparation method provided by the invention is simple, effective and high in yield. An in-vitro activity result proves that the compound shown in the formula (I) has the characteristics of broad-spectrum antibacterial activity, rapid sterilization, difficulty in generating drug resistance to bacteria and the like. Therefore, the compound is expected to be developed into a novel broad-spectrum antibacterial agent to resist bacterial infection.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. These compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as their main components, which may be isolated, purified, or extracted from cultivars and mixed together. The compositions include CBD, CBG, and THC in specific proportions, formulated for use in the treatment of PTE.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, addiction, epilepsy, depression, or Alzheimer's disease.

The present invention discloses the preparation and application of a cannabinoid monoclonal antibody, belonging to the field of biotechnology. The specific steps for the preparation of the cannabinoid monoclonal antibody include: (1) hapten preparation: reacting a cannabinoid molecule with methyl 4-chlorobenzoate to obtain the hapten; (2) complete antigen preparation: coupling the hapten with hemocyanin to obtain the complete antigen. The present invention prepares the complete antigens of tetrahydrocannabinol, cannabigerol or cannabidiol, further prepares the corresponding monoclonal antibodies, and then uses the prepared monoclonal antibodies to prepare a colloidal gold test strip. The prepared colloidal gold test strip has strong specificity and high sensitivity. The complete antigen is obtained by coupling a tetrahydrocannabinol, cannabigerol or cannabidiol molecule with hemocyanin.

The invention discloses a preparation method of cannabidiol and derivatives thereof, and belongs to the technical field of organic synthesis. According to the method, an allyl alcohol compound and a resorcinol compound are taken as raw materials and subjected to a Friedel-Crafts reaction under the action of boron trifluoride diethyl etherate / organic acid magnesium, cannabidiol and derivatives thereof are generated in a high-selectivity manner, further cyclization of products is inhibited, and generation of a byproduct cannabinol is avoided. The reaction has high chemical selectivity and good yield, the reaction condition is mild, the operation is simple, and the pollution is less. Meanwhile, a new CBD derivative can be generated by the process and is used for providing activity research of prototype molecules.

This disclosure generally relates to gas-phase methods to simultaneously purify and decarboxylate cannabinoids in about two seconds, which are about 100-10,000 times more efficient than conventional purification and decarboxylation strategies. The methods also recover thermolabile cannabinoids such as cannabigerol at significantly higher yields than conventional methods.

A method to treat the skin condition psoriasis is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The topical application is applied at least twice daily for six weeks.

The invention discloses a mutagenesis method and a cultivation method of industrial cannabis sativa, the mutagenesis method comprises the following steps: (1) soaking industrial cannabis sativa seeds with ethyl methanesulfonate, the concentration of the ethyl methanesulfonate being 0.05-0.4 mol / L, and the soaking time being 15-60 min; and (2) planting the mutagenized industrial cannabis sativa seeds in a greenhouse, eliminating plants with low cannabis sativa terpene phenol content generation by generation through continuous multi-generation selection, carrying out genetic diversity and genetic relationship analysis by utilizing a molecular marker technology, and screening the industrial cannabis sativa with improved cannabis sativa terpene phenol content. According to the method, ethyl methanesulfonate with specific concentration is matched with specific soaking time, the mutagenesis rate can be increased under optimized mutagenesis conditions, screening of variant plants is facilitated, and screening of industrial cannabis sativa with increased cannabinoid phenol content is facilitated.

A composition which provides a comprehensive solution for curbing, moderating and / or reducing the symptoms and cravings of opioid withdrawal syndrome. The composition is provided in the form of a capsule, pill, liquid, powder for mixing, or patch. In accordance with embodiments of the invention a composition for treating opioid withdrawal syndrome is provided. The composition includes (i) a therapeutically effective amount of a functional blend comprising a mixture of cannabidiol, cannabigerol, gamma aminobutyric acid, Inositol, and Vitamin B-12; (ii) a therapeutically effective amount of a hydration blend comprising a mixture of calcium, magnesium, potassium citrate, and L-glutamine; (iii) a therapeutically effective amount of an anti-inflammatory blend comprising a mixture of turmeric, green tea, and passion fruit; and (iv) a therapeutically effective amount of a neurotransmitter blend comprising 5-hydroxy-L-Tryptophan, N-acetyl L-Tyrosine, and L-Phenylalanine. The composition is consummate addition to a complete opioid cessation and withdrawal program because it targets, moderates, curbs and / or ameliorates the deleterious symptoms of opioid cessation and withdrawal. The composition is consummate addition to a complete opioid cessation and withdrawal program because it targets, moderates, curbs and / or ameliorates the potentially incessant drug cravings and the associated anxiety and stress.

Compositions that include cannabinoids other than tetrahydrocannabinol (THC), such as cannabigerol (CBG) in combination with tetrahydrocannabinol (THC) or formulated to be combined with THC, and methods of preparation and use thereof are described. The compositions may be useful to reduce the risk of THC-induced anxiety and / or to produce a different intoxicating effect compared to THC alone.

This invention provides enzymes and methods for synthesizing cannabinoids specifically and in high yield. [Solution] A method is provided for producing one or more cannabinoids, comprising the step of contacting cannabigerol acid with a cannabinoid synthase ortholog. The cannabinoid synthase ortholog is derived from an organism other than hemp (Cannabis sativa). Also disclosed are recombinant cells of Saccharomyces cerevisiae or Pichia pastoris, which contain nucleic acids encoding the cannabinoid synthase ortholog in their genome. The cannabinoid synthase ortholog is expressed in its active form in the recombinant cells.

The present invention relates to cannabigerol (CBG), a cannabinoid, for use in the treatment of chronic insomnia, sleeplessness and “staying in sleep” discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and / or hyperactivity. The invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid Cannabinodiol (CBND) for use in the treatment of chronic insomnia, sleeplessness and “staying in sleep” discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and / or hyperactivity, preferably wherein the ratio of CBG:CBND by weight is between 10:1 and 1:10. The invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid tetrahydrocannabinol (THC) for use in the treatment of chronic insomnia, sleeplessness and “staying in sleep” discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and / or hyperactivity. The present invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid tetrahydrocannabinol (THC) for use in the treatment of depression as anti-depressive and a remedy for a depressive mood, preferably wherein the ratio of CBG:THC by weight is between 10:1 and 1:10, more preferably between 1:5 and 5:1. The present invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid tetrahydrocannabinol (THC) for use as mood stabilizer and relaxator, preferably wherein the ratio of CBG:THC by weight is between 7:3 and 3:7, more preferably between 2:5 and 5:2.

The application discloses a cannabinoid 1 type receptor-mediated brain-targeting lipid nanocapsule drug loading system and a preparation and application thereof, and belongs to the technical field of targeted drugs. The brain-targeting lipid nanocapsule drug loading system comprises a drug-loaded lipid nanocapsule, the surface of the lipid nanocapsule is modified with a ligand compound of a CB1 receptor, and the ligand compound is one of quebrachamine, methoxylated myristicin, chelerythrine, ostruthol or cannabigerol. The application utilizes the lipid nanocapsule carrier to load a compound X with neuroprotective activity, prolongs the circulation time of the compound X in the body, adsorbs a ligand compound Y on the surface of the lipid nanocapsule, can specifically recognize the CB1 receptor highly expressed on the brain nerve epidermal cells, can transport across the blood-brain barrier, and improves the drug concentration in the brain tissue and cells. The preparation method provided by the application is simple in operation, easy to popularize, can be used for preparing drugs crossing the blood-brain barrier, and has a wide application prospect.

Provided are pharmaceutical compositions comprising cannabis such that when combusted produces cannabidiolic acid (CBDA) for inhalation. Also provided are pharmaceutical composition for inhalation by a subject comprising tetrahy drocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabigerol (CBG). Also provided are methods of enhancing cannabidiolic acid (CBDA) in a pharmaceutical composition for inhalation. Methods of use of embodiments of the pharmaceutical composition and kits comprising embodiments of the pharmaceutical composition are provided herein. Unit dosage form medicaments and compositions for vaporization by a subject comprising cannabinoids are also disclosed herein.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and / or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and / or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and / or prevention of malign skin disorders, in particular skin cancer.

To provide an autophagy-promoting composition which has autophagy promotion or antagonistic effect by using a plurality of cannabinoids in combination.SOLUTION: An autophagy-promoting composition containing cannabidiol and cannabigerol is provided. Thus, the autophagy-promoting composition can be provided which exhibits promotion of autophagy or antagonistic effect as a novel effect which cannot be achieved by using each cannabinoid alone.SELECTED DRAWING: Figure 4

This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.

Cannabinoid compositions formulated for use in the treatment of complex regional pain syndrome (CRPS) are described. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as main components, which may be isolated, purified, or extracted from cultivars and blended together. The compositions include CBD, CBG, and THC in specific ratios, formulated for use in the treatment of CRPS.

Cannabinoid compositions formulated for use in the treatment of Aromatase Inhibitor- Induced Arthralgia (AHA) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of AHA.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, the composition comprising cannabigerol and rivocernib as active ingredients, and a use thereof. The composition according to the present invention is based on the finding that remarkably excellent cancer inhibitory efficacy is exhibited when rivoceranib and cannabigerol and / or cannabidiol are used in combination, and thus a cancer treatment effect can be enhanced using the composition.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and / or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and / or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and / or prevention of malign skin disorders, in particular skin cancer.

The present disclosure relates to cannabigerol sulfonate esters of formula (1).